AlphaCrest Capital Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

AlphaCrest Capital Management’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-3,391	Closed	-$1.42M	–	144
2022 Q3	$1.42M	Buy	3,391 +2,693	+386%	+$1.34M	0.09%	397
2022 Q2	$346K	Sell	698 -1,511	-68%	-$787K	0.02%	1067
2022 Q1	$1.24M	Sell	2,209 -487	-18%	-$294K	0.07%	447
2021 Q4	$2.04M	Buy	2,696 +2,408	+836%	+$1.8M	0.08%	420
2021 Q3	$215K	Sell	288 -534	-65%	-$400K	0.01%	1202
2021 Q2	$530K	Sell	822 -1,212	-60%	-$738K	0.02%	940
2021 Q1	$1.16M	Buy	2,034 +193	+10%	+$114K	0.06%	433
2020 Q4	$1.07M	Buy	+1,841	New	+$1.05M	0.09%	297
2020 Q3	–	Sell	-574	Closed	-$259K	–	1090
2020 Q2	$259K	Sell	574 -904	-61%	-$399K	0.04%	699
2020 Q1	$518K	Sell	1,478 -410	-22%	-$151K	0.06%	552
2019 Q4	$699K	Buy	1,888 +388	+26%	+$137K	0.06%	564
2019 Q3	$499K	Sell	1,500 -610	-29%	-$199K	0.03%	913
2019 Q2	$660K	Buy	+2,110	New	+$632K	0.06%	587
2019 Q1	–	Sell	-1,600	Closed	-$372K	–	820
2018 Q4	$372K	Buy	+1,600	New	+$429K	0.11%	357

Other funds holding BIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

AlphaCrest Capital Management's BIO Position: Q4 2022 in Review

AlphaCrest Capital Management sold out of Bio-Rad Laboratories Class A (BIO) in Q4 2022, closing a stake of 3,391 shares — an estimated $1.42M sold.

AlphaCrest Capital Management first reported a position in BIO in Q4 2018 and held it in 14 quarters. The position peaked at $2.04M in Q4 2021. 472 funds tracked by Wall St. Rank hold BIO as of Q4 2022.

AlphaCrest Capital Management reported no remaining Bio-Rad Laboratories Class A position as of Q4 2022 after selling out during the quarter.
AlphaCrest Capital Management sold 3,391 Bio-Rad Laboratories Class A shares in Q4 2022, an estimated $1.42M.
AlphaCrest Capital Management first reported a position in Bio-Rad Laboratories Class A in Q4 2018 and held it in 14 quarters.
AlphaCrest Capital Management's Bio-Rad Laboratories Class A position peaked at $2.04M in Q4 2021.
472 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2022.

Based on AlphaCrest Capital Management's 13F filing for Q4 2022.